Mauna Kea Technologies and Tasly Pharmaceutical Group announced the achievement of anew key milestone in their strategic partnership. Tasly Mauna Kea Medical Engineering Technology Co. Ltd., based in the Zheijang province of China, is now legally incorporated with registered capital of RMB 250 million (EUR 35 million).

Tasly Mauna Kea Medical Engineering Technology Co. Ltd. will serve as the exclusive commercial platform for expanding the reach of Cellvizio into the Chinese domestic market and will launch a dedicated platform for neurosurgical applications worldwide.